TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07661797: A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Antitumor Efficacy of LNF2105 in Patients With Advanced Solid Tumors.

Sponsor: Shandong New Time Pharmaceutical Co., LTD · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 294 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07661797 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07661797 Rescue Dossier →